Cargando…

Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort

OBJECTIVES: The development of novel antiviral agents active against Hepatitis Delta Virus (HDV) might change the natural history of chronic infection, reducing the risk for end-stage liver disease. People living with HIV (PWH) are at risk for bloodborne pathogens infection, but limited data on epid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicolini, Laura Ambra, Menzaghi, Barbara, Ricci, Elena, Pontali, Emanuele, Cenderello, Giovanni, Orofino, Giancarlo, Cascio, Antonio, Pellicanò, Giovanni Francesco, Valsecchi, Laura, Molteni, Chiara, Vichi, Francesca, Bonfanti, Paolo, Di Biagio, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911436/ https://www.ncbi.nlm.nih.gov/pubmed/36778739 http://dx.doi.org/10.3389/fmed.2023.1086012

Ejemplares similares

Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?
por: Maggi, Paolo, et al.
Publicado: (2022)

Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study
por: De Vito, Andrea, et al.
Publicado: (2023)

Trajectories of CD4(+)/CD8(+) T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study
por: Taramasso, Lucia, et al.
Publicado: (2022)

Factors Associated With Weight Gain in People Treated With Dolutegravir
por: Taramasso, Lucia, et al.
Publicado: (2020)

Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir
por: Squillace, Nicola, et al.
Publicado: (2023)

Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
por: Maggi, Paolo, et al.
Publicado: (2023)

Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens
por: Maggi, Paolo, et al.
Publicado: (2023)

Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation
por: Cenderello, Giovanni, et al.
Publicado: (2015)

HTA and HIV: The Case of Dual NRTI Backbones in the Italian Setting
por: Garagiola, Elisabetta, et al.
Publicado: (2020)

Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)
por: Taramasso, Lucia, et al.
Publicado: (2019)

Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis
por: Cenderello, Giovanni, et al.
Publicado: (2017)

Reversibility of Central Nervous System Adverse Events in Course of Art
por: Taramasso, Lucia, et al.
Publicado: (2022)

Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study
por: Maggi, Paolo, et al.
Publicado: (2019)

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project
por: Bagella, Paola, et al.
Publicado: (2018)

Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study
por: Madeddu, G, et al.
Publicado: (2010)

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)
por: Taramasso, Lucia, et al.
Publicado: (2018)

Ten Years of Medical Informatics and Standards Support for Clinical Research in an Infectious Diseases Network
por: Mora, Sara, et al.
Publicado: (2023)

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
por: Bagella, Paola, et al.
Publicado: (2019)

The impact of PrEP: results from a multicenter Health Technology Assessment into the Italian setting
por: FERRARIO, LUCREZIA, et al.
Publicado: (2020)

Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project
por: Squillace, Nicola, et al.
Publicado: (2017)

Weight Gain: A Possible Side Effect of All Antiretrovirals
por: Taramasso, Lucia, et al.
Publicado: (2017)

Time to change the single-centre approach to management of patients with tuberculosis: a novel network platform with automatic data import and data sharing
por: Riccardi, Niccolò, et al.
Publicado: (2018)

Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study
por: De Socio, Giuseppe Vittorio, et al.
Publicado: (2020)

Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort
por: Bonfanti, Paolo, et al.
Publicado: (2020)

Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian “GEPPO” Cohort
por: Focà, Emanuele, et al.
Publicado: (2019)

HDV-Like Viruses
por: Pérez-Vargas, Jimena, et al.
Publicado: (2021)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
por: Squillace, Nicola, et al.
Publicado: (2020)

Treatment of hepatitis C virus genotype 4 in the DAA era
por: Di Biagio, Antonio, et al.
Publicado: (2018)

AAV-HDV: An Attractive Platform for the In Vivo Study of HDV Biology and the Mechanism of Disease Pathogenesis (†)
por: Maestro, Sheila, et al.
Publicado: (2021)

Circulation of HDV Genotypes in Brazil: Identification of a Putative Novel HDV-8 Subgenotype
por: Mello, Francisco C. A., et al.
Publicado: (2023)

Combination of Novel Therapies for HDV
por: Elazar, Menashe, et al.
Publicado: (2022)

A Review of HDV Infection
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

Variable In Vivo Hepatitis D Virus (HDV) RNA Editing Rates According to the HDV Genotype
por: Dziri, Samira, et al.
Publicado: (2021)

HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges
por: Sagnelli, Caterina, et al.
Publicado: (2021)

The Ligurian Human Immunodeficiency Virus Clinical Network: A Web Tool to Manage Patients With Human Immunodeficiency Virus in Primary Care and Multicenter Clinical Trials
por: Fraccaro, Paolo, et al.
Publicado: (2013)

HDV infection rates in northern Vietnam
por: Binh, Mai Thanh, et al.
Publicado: (2018)

HBV and HDV: New Treatments on the Horizon
por: Zuccaro, Valentina, et al.
Publicado: (2021)

HDV Pathogenesis: Unravelling Ariadne’s Thread
por: Tseligka, Eirini D., et al.
Publicado: (2021)

Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV
por: Mateo, Roberto, et al.
Publicado: (2023)

96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience
por: Capetti, Amedeo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8tp2k37d052t3onil2lg69om3l